"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 2 | 6 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 1 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 6 | 0 | 6 |
| 2002 | 5 | 7 | 12 |
| 2003 | 1 | 1 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 21 | 3 | 24 |
| 2006 | 10 | 3 | 13 |
| 2007 | 17 | 1 | 18 |
| 2008 | 19 | 3 | 22 |
| 2009 | 16 | 3 | 19 |
| 2010 | 17 | 2 | 19 |
| 2011 | 20 | 4 | 24 |
| 2012 | 10 | 2 | 12 |
| 2013 | 20 | 4 | 24 |
| 2014 | 21 | 1 | 22 |
| 2015 | 16 | 2 | 18 |
| 2016 | 27 | 3 | 30 |
| 2017 | 21 | 4 | 25 |
| 2018 | 18 | 1 | 19 |
| 2019 | 28 | 3 | 31 |
| 2020 | 16 | 3 | 19 |
| 2021 | 5 | 1 | 6 |
| 2022 | 19 | 0 | 19 |
| 2023 | 14 | 0 | 14 |
| 2024 | 18 | 1 | 19 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Dissecting tumor transcriptional heterogeneity from single-cell RNA-seq data by generalized binary covariance decomposition. Nat Genet. 2025 Jan; 57(1):263-273.
-
Assessment of intermediate-term mortality following pancreatectomy for cancer. J Natl Cancer Inst. 2025 Jan 01; 117(1):49-57.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor. J Clin Endocrinol Metab. 2024 Dec 18; 110(1):263-274.
-
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms. Immunity. 2024 12 10; 57(12):2879-2894.e11.
-
Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery. 2025 01; 177:108834.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
-
Quantitative SPECT/CT Metrics in Early Prediction of [177Lu]Lu-DOTATATE Treatment Response in Gastroenteropancreatic Neuroendocrine Tumor Patients. J Nucl Med. 2024 Oct 01; 65(10):1584-1590.
-
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024 Sep; 209:114236.